You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Cirrhosis with steatohepatitis following longterm stilboestrol treatment
  1. L Cooper1,
  2. M Palmer2,
  3. K Oien3
  1. 1University Department of Pathology, Royal Infirmary, Glasgow G4 OSF, UK; LornaAHCooper@aol.com
  2. 2Department of Urology, Gartnavel General Hospital, Glasgow G12 0YN, UK
  3. 3University Department of Pathology, Royal Infirmary, Glasgow

    https://doi.org/10.1136/jcp.56.8.639

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      Diethylstilboestrol, which is chemically related to the female hormone oestrogen, was the main form of androgen suppression in the treatment of advanced prostate cancer up until the late 1980s.1 Although luteinising hormone releasing hormone (LHRH) analogues have superseded diethylstilboestrol over the past 10 to 15 years, it is relatively common in clinical practice to encounter patients who are still taking diethylstilboestrol. Adverse hepatic reactions involving diethylstilboestrol have been reported in animal models,2 but are still relatively uncharacterised in humans.

      We describe a case in which a patient was started on stilboestrol (1 mg twice daily) at age 65, after …

      View Full Text